BR112014032847A2 - uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundário - Google Patents
uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundárioInfo
- Publication number
- BR112014032847A2 BR112014032847A2 BR112014032847A BR112014032847A BR112014032847A2 BR 112014032847 A2 BR112014032847 A2 BR 112014032847A2 BR 112014032847 A BR112014032847 A BR 112014032847A BR 112014032847 A BR112014032847 A BR 112014032847A BR 112014032847 A2 BR112014032847 A2 BR 112014032847A2
- Authority
- BR
- Brazil
- Prior art keywords
- secondary hyperparathyroidism
- 1alpha
- methylene
- treatment
- dihydroxycivilamine
- Prior art date
Links
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 title abstract 4
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
resumo uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundário (pt) descreve-se a utilização de 2-methy1ene-i9-nor- (20s) -la, 25-dihydroxwitamin d3 para tratar e / ou prevenir o hiperparatiroidismo secundário e / ou os seus sintomas que acompanham em um sujeito com ou em risco de desenvolver secundário hiperparatireoidismo sem induzir hipercalcemia no assunto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261666264P | 2012-06-29 | 2012-06-29 | |
PCT/US2013/031574 WO2014003849A1 (en) | 2012-06-29 | 2013-03-14 | USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014032847A2 true BR112014032847A2 (pt) | 2017-06-27 |
Family
ID=47997980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014032847A BR112014032847A2 (pt) | 2012-06-29 | 2013-03-14 | uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundário |
Country Status (19)
Country | Link |
---|---|
US (4) | US9205096B2 (pt) |
EP (1) | EP2866811A1 (pt) |
JP (1) | JP2015522015A (pt) |
KR (1) | KR20150030673A (pt) |
CN (1) | CN104394871A (pt) |
AU (1) | AU2013281217B2 (pt) |
BR (1) | BR112014032847A2 (pt) |
CA (1) | CA2877680C (pt) |
CL (1) | CL2014003565A1 (pt) |
CO (1) | CO7240358A2 (pt) |
HK (1) | HK1206600A1 (pt) |
IL (1) | IL236184A0 (pt) |
MX (1) | MX2015000076A (pt) |
MY (1) | MY172886A (pt) |
NZ (1) | NZ703347A (pt) |
RU (1) | RU2666995C2 (pt) |
SG (1) | SG11201408731WA (pt) |
WO (1) | WO2014003849A1 (pt) |
ZA (1) | ZA201500119B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015522015A (ja) * | 2012-06-29 | 2015-08-03 | ウイスコンシン アラムニ リサーチ ファンデーション | 続発性副甲状腺機能亢進症を治療するための2−メチレン−19−ノル−(20S)−1α,25−ジヒドロキシビタミンD3の使用 |
DK3049979T3 (da) * | 2013-09-27 | 2020-02-17 | Codexis Inc | Struktur-baseret prædiktiv konstruktion |
RU2016116253A (ru) | 2013-09-27 | 2017-11-01 | Кодексис, Инк. | Автоматизированный скрининг вариантов фермента |
CN103533522A (zh) * | 2013-10-25 | 2014-01-22 | 从兴技术有限公司 | 短信稽核的方法及*** |
EP3193925A2 (en) * | 2014-08-07 | 2017-07-26 | OPKO Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
US10369161B2 (en) | 2014-12-30 | 2019-08-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
WO2018044468A1 (en) | 2016-08-30 | 2018-03-08 | Wisconsin Alumni Research Foundation | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
US6306844B1 (en) | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
US6136799A (en) | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
US6673782B2 (en) | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
EP1267886B1 (en) | 2000-03-27 | 2006-03-08 | Wisconsin Alumni Research Foundation | Vitamin d compounds for the treatment of chronic allograft nephropathy in kidney transplant patients |
NZ537036A (en) | 2000-07-14 | 2006-07-28 | Wisconsin Alumni Res Found | Use of 2-methylene-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 to increase bone strength |
US20080249068A1 (en) | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
US20060171983A1 (en) | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
NZ545632A (en) * | 2003-09-19 | 2009-09-25 | Wisconsin Alumni Res Found | 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia |
US7704980B2 (en) | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
US7214671B2 (en) | 2004-02-19 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases |
MX2007009726A (es) | 2005-02-11 | 2007-09-26 | Wisconsin Alumni Res Found | 2-metilen-19-nor-(20s-24s)-1a, 25-dihidroxivitamina-d2. |
US7528122B2 (en) * | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
WO2011017165A1 (en) * | 2009-08-03 | 2011-02-10 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
WO2011119610A2 (en) | 2010-03-23 | 2011-09-29 | Wisconsin Alumni Research Foundation | (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3 |
JP2015522015A (ja) * | 2012-06-29 | 2015-08-03 | ウイスコンシン アラムニ リサーチ ファンデーション | 続発性副甲状腺機能亢進症を治療するための2−メチレン−19−ノル−(20S)−1α,25−ジヒドロキシビタミンD3の使用 |
-
2013
- 2013-03-14 JP JP2015520165A patent/JP2015522015A/ja active Pending
- 2013-03-14 CN CN201380034681.7A patent/CN104394871A/zh active Pending
- 2013-03-14 RU RU2015102831A patent/RU2666995C2/ru not_active IP Right Cessation
- 2013-03-14 NZ NZ703347A patent/NZ703347A/en not_active IP Right Cessation
- 2013-03-14 BR BR112014032847A patent/BR112014032847A2/pt not_active Application Discontinuation
- 2013-03-14 WO PCT/US2013/031574 patent/WO2014003849A1/en active Application Filing
- 2013-03-14 AU AU2013281217A patent/AU2013281217B2/en not_active Ceased
- 2013-03-14 CA CA2877680A patent/CA2877680C/en not_active Expired - Fee Related
- 2013-03-14 KR KR20147036464A patent/KR20150030673A/ko not_active Application Discontinuation
- 2013-03-14 MX MX2015000076A patent/MX2015000076A/es unknown
- 2013-03-14 SG SG11201408731WA patent/SG11201408731WA/en unknown
- 2013-03-14 US US13/828,090 patent/US9205096B2/en not_active Expired - Fee Related
- 2013-03-14 MY MYPI2014003594A patent/MY172886A/en unknown
- 2013-03-14 EP EP13712121.6A patent/EP2866811A1/en not_active Withdrawn
-
2014
- 2014-03-07 US US14/201,091 patent/US9034853B2/en not_active Expired - Fee Related
- 2014-12-11 IL IL236184A patent/IL236184A0/en unknown
- 2014-12-29 CL CL2014003565A patent/CL2014003565A1/es unknown
-
2015
- 2015-01-08 ZA ZA2015/00119A patent/ZA201500119B/en unknown
- 2015-01-23 CO CO15013584A patent/CO7240358A2/es unknown
- 2015-07-24 HK HK15107093.4A patent/HK1206600A1/xx unknown
- 2015-11-20 US US14/947,142 patent/US9717744B2/en not_active Expired - Fee Related
-
2017
- 2017-05-24 US US15/604,069 patent/US10046000B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20140005152A1 (en) | 2014-01-02 |
US10046000B2 (en) | 2018-08-14 |
IL236184A0 (en) | 2015-01-29 |
AU2013281217A1 (en) | 2015-01-22 |
JP2015522015A (ja) | 2015-08-03 |
RU2015102831A (ru) | 2016-08-20 |
CA2877680C (en) | 2017-08-29 |
EP2866811A1 (en) | 2015-05-06 |
HK1206600A1 (en) | 2016-01-15 |
US20170252360A1 (en) | 2017-09-07 |
MY172886A (en) | 2019-12-13 |
KR20150030673A (ko) | 2015-03-20 |
US9034853B2 (en) | 2015-05-19 |
US9205096B2 (en) | 2015-12-08 |
MX2015000076A (es) | 2015-04-10 |
CL2014003565A1 (es) | 2015-08-28 |
WO2014003849A1 (en) | 2014-01-03 |
US20160136184A1 (en) | 2016-05-19 |
CA2877680A1 (en) | 2014-01-03 |
NZ703347A (en) | 2016-05-27 |
CN104394871A (zh) | 2015-03-04 |
ZA201500119B (en) | 2017-11-29 |
RU2666995C2 (ru) | 2018-09-13 |
SG11201408731WA (en) | 2015-01-29 |
AU2013281217B2 (en) | 2017-03-02 |
US9717744B2 (en) | 2017-08-01 |
US20140187522A1 (en) | 2014-07-03 |
CO7240358A2 (es) | 2015-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014032847A2 (pt) | uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundário | |
BR112018013074A2 (pt) | terapias de célula efetora imune com eficácia real-çada | |
BR112016023720A2 (pt) | nebulizador | |
BR112017007777A2 (pt) | canabidiol para uso, método para tratar convulsões atônicas, e, composição. | |
BR112016012968A2 (pt) | Métodos e composições para o tratamento de condições associadas com o envelhecimento | |
BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
CL2014002915A1 (es) | Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico. | |
CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
BR112014019331A2 (pt) | anticorpos para cd47 e métodos de uso desses | |
CL2013003638A1 (es) | Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas. | |
BR112016008409A2 (pt) | Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2 | |
BR112018074454A2 (pt) | composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal | |
NI201400144A (es) | Métodos para el tratamiento del s | |
CL2019001258A1 (es) | Métodos para tratar el síndrome de alport usando bardoxolona metilo o análogos de la misma. | |
BR112015006847A2 (pt) | um elemento auxiliar de barbeamento ou depilação de contato com a pele que compreende ao menos uma substância sensibilizante termicamente resiliente | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
BR112014004929A2 (pt) | conversão de unidades de alquilação de hf para processos de alquilação catalisada por líquido iônico | |
CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
CR20150390A (es) | Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2) | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
BR112015027477A8 (pt) | bolus, seus usos, e kit | |
BR112013008492A2 (pt) | recipiente de revelador, dispositivo de revelação, cartucho de processo, dispositivo de formação de imagem, e método de reabastecimento de revelador | |
BR112014031112A2 (pt) | nanossistemas para formulação de biocidas eficazes de risco mínimo | |
BR112017000978A2 (pt) | mioinositol e probióticos e usos | |
BR112015025719A2 (pt) | terapia contra o câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |